Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined
in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed
using treatment regimen evaluated in dose escalation part in participants with breast cancer
(up to 3 prior regimens of chemotherapy) in the expansion part 1 and in participants with
adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), small cell lung
cancer (SCLC) and breast cancer (with no prior regimens of chemotherapy) in the expansion
part 2, 3, 4, 5 and 6 respectively.